Search results
Showing 151 to 200 of 298 results for breast cancer
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)
Evidence-based recommendations on everolimus (Afinitor) for treating advanced breast cancer in adults after endocrine therapy.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Price discount helps give green light for breast cancer drug pertuzumab
NICE approves the third breast cancer drug is as many weeks as pertuzumab is recommended to shrink tumours in some people with breast cancer so surgery can take place.
This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.
NICE has developed a medtech innovation briefing (MIB) on OSNA for colon cancer staging
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
This quality standard covers the care of people with breast cancer after they have been referred to a specialist team. It includes the management of early (ductal carcinoma in situ and invasive), locally advanced and advanced breast cancer; recurrent breast cancer; and familial breast cancer. It describes high-quality care in priority areas for improvement.
View quality statements for QS12Show all sections
Sections for QS12
- Introduction
- List of quality statements
- Quality statement 1: Timely diagnosis
- Quality statement 2: Preoperative MRI scan
- Quality statement 3: Gene expression profiling
- Quality statement 4: ER and HER2 receptor status
- Quality statement 5: Multidisciplinary team management of metastatic breast cancer
- Quality statement 6: Key worker
increased risk of colorectal cancer:- How effective are colonoscopic surveillance programmes in improving overall survival and...
Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron (ESNM69)
Summary of the evidence on netupitant/palonosetron to prevent chemotherapy induced nausea and vomiting to inform local NHS planning and decision-making
NICE has welcomed proposed new guidelines on alcohol which aim to limit the health risks that result from drinking.
NG23/2 Question Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal...
Recommendation ID NG23/1 Question Women with breast cancer:- What is the safety and effectiveness of alternatives to systemic HRT as...
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
EndoPredict gene expression profiling assay for assessing risk of breast cancer recurrence (MIB44)
This advice has been updated and replaced by NICE diagnostics guidance 34.
premature ovarian insufficiency and women with hormone-sensitive cancer (for example, breast cancer). This guideline is...
Source guidance details Comes from guidance Advanced breast cancer: diagnosis and treatment Number CG81 Date issued
Thousands of lives in England could be saved each year if the NHS follows updated guidance to help it diagnose cancer earlier. Here we outline what the guidance means for GPs.
women over 50 years with a personal history of breast cancer. Studies should include sub-analysis for breast density. [new...
combination with a taxane for the first-line treatment of metastatic breast cancer Number TA214 Date issued February 2011 Other
of mutations and need adjustment for pathological subtypes of breast and ovarian cancer, which are particularly associated...
CG164/4 Question Chemoprevention to reduce incidence of breast cancer:- A randomised controlled trial is recommended to compare the...
combination with capecitabine for the first-line treatment of metastatic breast cancer Number TA263 Date issued August 2012 Other
RD-100i OSNA system in detecting sentinel lymph node metastases during breast cancer surgery. It also recommends that data on all...
creating rapid access to genetic testing for people with newly diagnosed breast cancer. This research should address the optimum model...
Studies show that risk-reducing surgery significantly reduces risk of breast cancer, but there is insufficient evidence to decide...
This advice has been updated and replaced by NICE diagnostics guidance 34.
This guideline covers behaviours such as diet and physical activity to help children (after weaning), young people and adults maintain a healthy weight or help prevent excess weight gain. The aim is to prevent a range of diseases and conditions including cardiovascular disease and type 2 diabetes and improve mental wellbeing.
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Introduction
- List of quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
NICE has developed a Medtech Innovation Briefing (MIB) on Aixplorer ShearWave Elastography for ultrasound imaging and assessing suspicious breast lesions
This guideline covers the nutrition of pregnant women, including women who are planning to become pregnant, mothers and other carers of children aged under 5 and their children. In particular, it aims to address disparities in the nutrition of low-income and other disadvantaged groups compared with the general population.
Interim methods guide for developing service guidance 2014 (PMG8)
Interim methods guide for developing service guidance 2014
This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.
Weight management: lifestyle services for overweight or obese adults (PH53)
This guideline covers multi-component lifestyle weight management services including programmes, courses, clubs or groups provided by the public, private and voluntary sector. The aim is to help people lose weight and become more physically active to reduce the risk of diseases associated with obesity. This includes coronary heart disease, stroke, type 2 diabetes and various cancers.
Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)
Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making
Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013
This guidance has been updated and replaced by NICE technology appraisal guidance TA421.
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery
Physical activity: brief advice for adults in primary care (PH44)
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
Evidence-based recommendations on bevacizumab (Avastin), with gemcitabine and carboplatin, for treating platinum-sensitive advanced ovarian cancer in adults.
What are the options for women with inherited breast cancer?
Following Angelina Jolie?s decision to go public with the news that she has had a double mastectomy for breast cancer, we explore who is at risk and the treatment options available for women on the NHS.
Electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma (IPG446)
Evidence-based recommendations on electrochemotherapy for metastases in the skin from tumours of non-skin origin and melanoma. This involves applying short, powerful pulses of electricity to the tumour, allowing an anticancer drug to pass through into the cells.
View recommendations for IPG446Show all sections
Sections for IPG446
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making
Irreversible electroporation for treating primary lung cancer and metastases in the lung (IPG441)
Evidence-based recommendations on irreversible electroporation for treating primary lung cancer and metastases in the lung. This involves using electrical pulses to kill cancer cells.
View recommendations for IPG441Show all sections
Sections for IPG441
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Uptake of NICE-approved medicines on the NHS to treat cardiovascular disease, diabetes and osteoporosis is higher than expected, latest figures reveal.